| abstract |
The present invention relates to rifamycin analogs that can be used as therapeutic agents to treat and prevent various microbial infections. In one form, the analog of the invention is rifamycin, which is acylated at the 25-position. Another type of analog is deacylated at the 25-position. In another form, the benzoxazinolipamycin, benzthiazinolifamycin, and benzdiazinolipamycin analogs are 3'- hydroxyl analogs and / or benzene rings at the 4 ', 5' or 5 ', 6' sites. Derived at various sites in the benzene ring, including various ring systems fused with |